Enveric Biosciences
ENVB
1 hedge funds and large institutions have $90K invested in Enveric Biosciences in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
500% more capital invested
Capital invested by funds: $15K → $90K (+$75K)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $70K | +$47.3K | +1 | New |
|
2
Geode Capital Management
Boston,
Massachusetts
| $16K | – | – | – |
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
4
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
ENVB Hedge Fund Activity: Q2 2020 in Review
1 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q2 2020, worth a combined $90K — up 500% from $15K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ENVB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
- 1 institutional investor held Enveric Biosciences (ENVB) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $90K of Enveric Biosciences stock for Q2 2020, up 500% quarter-over-quarter.
- 1 fund opened new Enveric Biosciences positions in Q2 2020 and 0 closed out, a net change of +1 holder.
Based on aggregated 13F filings for Q2 2020.